PDF factsheet
      Z

antiplatelets drug in cardiovascular prevention for primary prevention, clinical trials results

aspirin versus no treatment
British Doctor’s Trial, 1988
aspirin 500 mg/d
versus
no aspirin
apparently healthy male doctorsopen
Follow-up duration: 5.5 years
UK
Primary Prevention Project, 2001
aspirin 100 mg/d
versus
no aspirin (open control)
men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors.Open
Follow-up duration: 3.6 y
Italy
aspirin versus placebo
AAA, 2009
ISRCTN66587262
aspirin 100mg daily
versus
placebo
men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95)double blind
Follow-up duration: 8.2 y (mean)
UK, Scotland
ASPREE, 2018
NCT01038583

versus
ASCEND, 2018
NCT00135226

versus
Physicians Health Study, 1989
NCT00000500
aspirin 325 mg every other day
versus
placebo
Healthy mendouble blind
Follow-up duration: 60.2 months
Thrombosis Prevention Trial, 1998
NCT00000614
aspirin 75 mg/d (controlled release)
versus
placebo
Men at high risk of CHDdouble blind
Follow-up duration: median 6.8y
UK
HOT, 1998
aspirin 75 mg daily
versus
placebo
patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHGDouble blind
Follow-up duration: mean 3.8 y (range 3.3-4.9y)
Europe, North and South America, and Asia
Women’s Health Study, 2005
aspirin 100mg daily
versus
placebo
initially healthy women 45 years of age or olderDouble blind
Follow-up duration: 10.1 y mean (range 8.2 to 10.9

  Options


in first

in second

  Filter